Advertisement

Ascertainment of Side Effects in Psychopharmacologic Clinical Trials

  • J. Levine
Part of the Psychopharmacology Series book series (PSYCHOPHARM, volume 8)

Abstract

Since the era of modern pharmacologic treatment of psychiatric disorders began in the mid-1950s, much progress has been made in techniques to assess the efficacy of proposed therapeutic agents. This has come about for a variety of reasons including the amendment to the U.S. Food, Drug, and Cosmetics Law in 1962 that requires proof of efficacy before marketing of prescription medications is permitted. Assessment or proof of safety prior to marketing had been a requirement for many years.

Keywords

Adverse Drug Reaction Adverse Health Event Efficacy Assessment Intercurrent Illness Drug Surveillance 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Downing RW, Rickels K, Meyers F (1970) Side reactions in neurotics: a comparison of two methods of assessment. J Clin Pharmacol 10: 289–297CrossRefGoogle Scholar
  2. Faich GA (1986) Adverse drug reaction monitoring. N Engl J Med 314: 1589–1592PubMedCrossRefGoogle Scholar
  3. Fisher S, Bryant SG, Kluge RM (1987) Detecting adverse drug reactions in post marketing surveillance: interview-validity. Drug Inform J 21: 173–183Google Scholar
  4. Fletcher RH, Fletcher SW, Wagner EH (1982) Clinical epidemiology — the essentials. Williams and Wilkins, BaltimoreGoogle Scholar
  5. Jick H, Miettinen OS, Shapiro S et al. (1970) Comprehensive drug surveillance. J Am Med Assoc 215: 1455–1460CrossRefGoogle Scholar
  6. Jones JK, Herman RL (1986) The future of adverse drug reaction diagnosis: computers, clinical judgement and the logic of uncertainty. Drug Inform J 20 /4: 445–535Google Scholar
  7. Koeppen K, Mohr R, Streichenwein SM (1989) Assessment of adverse drug events during the clinical investigation of a new drug. Pharmacopsychiatry 22: 93–98PubMedCrossRefGoogle Scholar
  8. Levine J, Schooler NR (1986) SAFTEE: a technique for the systematic assessment of side effects in clinical trials. Psychopharmacol Bull 22: 343–381PubMedGoogle Scholar
  9. Markowitz JS, Rabkin JG, Stewart J, Tricamo E, McGrath PJ, Harrison W, Ocepek-Welikson K, Quitkin FM (1987) Validity assessment of SAFTEE: a preliminary report. Psychopharmacol Bull 23: 102–105PubMedGoogle Scholar
  10. Mellinger GD, Baiter MB, Abramowitz S, Schaffer CB, Bernstein LR (1988) Survey method for post marketing drug surveillance. J Clin Psychopharmacol 8: 168–176PubMedCrossRefGoogle Scholar
  11. O’Neill RT (1988) Assessment of Safety. In: Peace KE (ed) Biopharmaceutical statistics for drug development. Dekker, New YorkGoogle Scholar
  12. Peace KE (1987) Design, monitoring and analysis issues relative to adverse events. Drug Inform J 21: 21–28Google Scholar
  13. Petrie WM, Levine J (1978) The assessment of adverse reactions in clinical trials. Int Pharmacopsychiatry 13: 209–216PubMedGoogle Scholar
  14. Skegg D, Doll R (1977) The case for recording events in clinical trials. Br Med J 2: 1523–1524PubMedCrossRefGoogle Scholar
  15. Speiss-Kiefer C, Grohmann R, Schmidt LG, Ruther E (1988) Six years of drug surveillance in psychiatric inpatients. Pharm Med 3: 341–348Google Scholar
  16. Stephens MDP (1985) The detection of new adverse drug reactions. Macmillan, LondonGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • J. Levine
    • 1
  1. 1.Maryland Psychiatric Research Center, Department of PsychiatryUniversity of MarylandBaltimoreUSA

Personalised recommendations